A recent trial reveals metformin does not enhance survival in metastatic prostate cancer but offers significant metabolic ...

So when my urologist said in 2019 that my PSA test showed the most aggressive form of prostate cancer, I was not prepared. I was 68, and my annual tests had always been normal. Soon I embarked on a ...

Androgen deprivation therapy (ADT) becomes less effective over time, but additional therapies like androgen receptor blockers and androgen synthesis inhibitors may extend life and improve the ...

The effectiveness of primary androgen-deprivation therapy (PADT) for clinically localized prostate cancer has been found lacking. A retrospective cohort study of more than 15,000 men newly ...

Data from clinical trials have indicated that PSA is prognostic for outcomes, but little is known about real-world trends.

Androgen deprivation therapy (ADT) has long been a foundation in the management of prostate cancer. Since the introduction of ...

Background: Prostate cancer (PC) is often treated with androgen-deprivation therapy (ADT), but progression remains a challenge. Darolutamide, a next-generation androgen receptor inhibitor, may improve ...

Darolutamide receives EU approval in third indication for patients with advanced prostate cancer European Commission granted ...

Background: Intermittent (i) and continuous (c) androgen deprivation therapy (ADT) not only play a critical role in managing prostate cancer (PC) but also impact patient’s quality of life (QoL). This ...

Investigators evaluated the effectiveness of an immunotherapy in combination with standard radiation therapy for patients with intermediate-high risk localized prostate cancer.